<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="145166">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01210859</url>
  </required_header>
  <id_info>
    <org_study_id>URSTDETRUSITOL</org_study_id>
    <nct_id>NCT01210859</nct_id>
  </id_info>
  <brief_title>Effects of Antimuscarinic Drugs on Overactive Bladder (OAB) Symptoms After Insertion of Ureteral Stents</brief_title>
  <official_title>Effects of Antimuscarinic Drugs on OAB Symptoms After Insertion of Ureteral Stents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meir Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Meir Medical Center</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to check whether antimuscarinics that usually broadly used in
      the treatment of overactive bladder symptoms are effective in the treatment of those
      symptoms after insertion of ureteral stents. In order to study the efficacy of the treatment
      of OAB symptoms in stented patients the investigator will use a suitable questionnary.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>Ureteral stents Detrusitol treatment Lyfestyle outcome</arm_group_label>
    <description>Ureteral stents Detrusitol treatment Lyfestyle outcome</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        patients which underwent ureteral stent insertion
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  everyone who underwent ureteral stent insertion and started the treatment with
             detrusitol

        Exclusion Criteria:

          -  adverse affects of detrusitol or unwillness of the patient to continue the treatment
             with detrusitol, cronic renal or hepatic failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 25, 2013</lastchanged_date>
  <firstreceived_date>September 28, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>detrusitol</keyword>
  <keyword>overactive</keyword>
  <keyword>bladder</keyword>
  <keyword>ureteral</keyword>
  <keyword>stents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tolterodine Tartrate</mesh_term>
    <mesh_term>Muscarinic Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
